Daniel Lysák

2.8k total citations · 3 hit papers
83 papers, 1.9k citations indexed

About

Daniel Lysák is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Daniel Lysák has authored 83 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 34 papers in Genetics and 20 papers in Immunology. Recurrent topics in Daniel Lysák's work include Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Daniel Lysák is often cited by papers focused on Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Daniel Lysák collaborates with scholars based in Czechia, United States and United Kingdom. Daniel Lysák's co-authors include Pavel Jindra, Mark D. Minden, Grzegorz Mazur, Jiří Mayer, Ching-Yuan Kuo, Xavier Thomas, Albert Oriol, Christopher Arthur, Rena Buckstein and Jaroslav Čermák and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel Lysák

73 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025 21 citations Wojciech Jurczak, Małgorzata Wach et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Lysák Czechia	18	1.1k	671	585	407	347	83	1.9k
Donna L. Forrest Canada	27	1.4k 1.3×	737 1.1×	422 0.7×	482 1.2×	392 1.1×	110	2.3k
Blanca Xicoy Spain	22	1.0k 1.0×	829 1.2×	436 0.7×	622 1.5×	605 1.7×	110	2.0k
Alfonso Piciocchi Italy	25	1.0k 1.0×	525 0.8×	330 0.6×	488 1.2×	353 1.0×	105	1.8k
Thomas J. Nevill Canada	25	1.8k 1.7×	632 0.9×	471 0.8×	761 1.9×	422 1.2×	99	2.5k
Herbert G. Sayer Germany	24	1.4k 1.3×	533 0.8×	475 0.8×	492 1.2×	218 0.6×	90	2.1k
Tariq I. Mughal United States	21	888 0.8×	788 1.2×	463 0.8×	430 1.1×	182 0.5×	115	1.7k
Taiga Nishihori United States	22	984 0.9×	231 0.3×	390 0.7×	751 1.8×	235 0.7×	169	1.7k
Cynthia L. Toze Canada	26	1.3k 1.2×	685 1.0×	192 0.3×	614 1.5×	568 1.6×	72	2.1k
Maria Gilleece United Kingdom	20	535 0.5×	405 0.6×	299 0.5×	278 0.7×	197 0.6×	54	1.4k
Pietro Pioltelli Italy	23	969 0.9×	778 1.2×	195 0.3×	319 0.8×	302 0.9×	80	2.0k

Countries citing papers authored by Daniel Lysák

Since Specialization

Citations

This map shows the geographic impact of Daniel Lysák's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lysák with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lysák more than expected).

Fields of papers citing papers by Daniel Lysák

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Lysák. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lysák. The network helps show where Daniel Lysák may publish in the future.

Co-authorship network of co-authors of Daniel Lysák

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Lysák. A scholar is included among the top collaborators of Daniel Lysák based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Lysák. Daniel Lysák is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ostašov, Pavel, Alexandra Jungová, Valentina S. Caputo, et al.. (2024). Lymphocyte profile in peripheral blood of patients with multiple myeloma. Annals of Hematology. 103(12). 5615–5625. 1 indexed citations

Truxová, Iva, Jana Raková, Cyril Šálek, et al.. (2023). Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients. Cell Death and Disease. 14(3). 209–209. 15 indexed citations

Reischig, Tomáš, Martin Kacer, Kristýna Pivovarčíková, et al.. (2023). A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. Journal of the American Society of Nephrology. 34(5). 920–934. 12 indexed citations

Jungová, Alexandra, et al.. (2023). Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience. Neoplasma. 70(2). 294–299. 2 indexed citations

Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →

Pitule, Pavel, Pavel Ostašov, Valentina S. Caputo, et al.. (2020). Dynamic Changes of Inhibitory Killer-Immunoglobulin-Like Receptors on NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation: An Initial Study. Journal of Clinical Medicine. 9(11). 3502–3502. 4 indexed citations

Reischig, Tomáš, Martin Kacer, Ondřej Hes, et al.. (2019). Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. American Journal of Transplantation. 19(9). 2457–2467. 26 indexed citations

Salles, Gilles, Emmanuel Bachy, Lukáš Smolej, et al.. (2019). Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Annals of Hematology. 98(12). 2749–2760. 11 indexed citations

10.

Reischig, Tomáš, Martin Kacer, Petra Hrubá, et al.. (2018). Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. BMC Infectious Diseases. 18(1). 573–573. 17 indexed citations

11.

Georgiev, V., et al.. (2018). 2DEP cytometry: distributed dielectrophoretic cytometry for live cell dielectric signature measurement on population level. Biomedical Microdevices. 20(1). 12–12. 7 indexed citations

12.

Třeška, Vladislav, Jan Brůha, Václav Liška, et al.. (2018). Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases. Anticancer Research. 38(9). 5531–5537. 6 indexed citations

13.

Lysák, Daniel, et al.. (2018). Mesenchymal stem cells as the near future of cardiology medicine - truth or wish?. Biomedical Papers. 163(1). 8–18. 8 indexed citations

14.

Třeška, Vladislav, et al.. (2017). Portal Vein Embolization with Contralateral Application of Stem Cells Facilitates Increase of Future Liver Remnant Volume in Patients with Liver Metastases. CardioVascular and Interventional Radiology. 40(5). 690–696. 8 indexed citations

15.

Lysák, Daniel, et al.. (2016). The Quality Control of Mesenchymal Stromal Cells by in Vitro Testing of Their Immunomodulatory Effect on Allogeneic Lymphocytes. Folia Biologica. 62(3). 120–130. 7 indexed citations

16.

Lysák, Daniel, Monika Holubová, Tamara Bergerová, et al.. (2015). Validation of shortened 2-day sterility testing of mesenchymal stem cell-based therapeutic preparation on an automated culture system. Cell and Tissue Banking. 17(1). 1–9. 14 indexed citations

17.

Reischig, Tomáš, Martin Kacer, Pavel Jindra, et al.. (2014). Randomized Trial of Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation. Clinical Journal of the American Society of Nephrology. 10(2). 294–304. 31 indexed citations

18.

Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677. 818 indexed citations breakdown →

19.

Tůma, Zdeněk, et al.. (2010). Proteomic profiling of blood‐dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis‐induced inflammatory response. PROTEOMICS - CLINICAL APPLICATIONS. 4(10-11). 829–838. 49 indexed citations

20.

Jindra, Pavel, et al.. (2010). Distribution of KIR genes in the population of unrelated individuals homozygous for ancestral haplotype AH8.1 (HLA-A1B8DR3). Tissue Antigens. 76(3). 240–244.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact